Expertise in
6
conditions

Dr. John Welch

Oncology
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
Expertise in
6
conditions
Washington University
660 S Euclid Ave, 
Saint Louis, MO 

Overview

John Welch is an Oncologist practicing medicine in Saint Louis, Missouri.

Dr. Welch is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 74 peer reviewed articles and participating in 18 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Washington University
660 S Euclid Ave, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: March 16, 2026
Intervention Type: Procedure
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Procedure
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Drug, Procedure
Study Drug: Duvelisib
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other, Procedure
Study Drug: Itacitinib
Study Phase: Phase 1
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, ALT-803, Cytokine-Induced Natural Killer T Cells, IL-2
Study Phase: Phase 1/Phase 2
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: ApoGraft
Study Phase: Phase 1
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 1
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: June 02, 2022
Intervention Type: Procedure, Drug
Study Drug: Decitabine
Study Phase: Phase 2
View 9 Less Clinical Trials

74 Total Publications

Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.
Corrigendum to "Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine" Experimental Hematology. 2022;111:50-65.
Journal: Experimental hematology
Published: March 29, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Nancy Bartlett
Oncology
Expertise in
34
conditions
Dr. Nancy Bartlett
Oncology

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Nancy Bartlett is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Bartlett is highly rated in 34 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
16
conditions
Dr. Ramaswamy Govindan
Oncology
Expertise in
16
conditions
Dr. Ramaswamy Govindan
Oncology

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Ramaswamy Govindan is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Govindan is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Expertise in
27
conditions
Dr. Angela Hirbe
Oncology
Expertise in
27
conditions
Dr. Angela Hirbe
Oncology

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7216
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Angela Hirbe is an Oncologist practicing medicine in Saint Louis, Missouri. She has been practicing medicine for over 17 years. Dr. Hirbe is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Neurofibromatosis Type 1 (NF1), and Adult Soft Tissue Sarcoma.

Frequently Asked Questions about Dr. John Welch

How do I make an appointment with Dr. John Welch?

You can book an appointment with Dr. John Welch by calling their office at 314-747-1171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Welch a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Welch is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Welch specialize in?

While Dr. John Welch is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. John Welch participate in research or clinical trials?

Yes. Dr. John Welch has published 74 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. John Welch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Welch's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile